retatrutide ly3437943 phase 2 trial obesity nejm 2023 isn't a GLP-1. It's not a dual agonist. It's a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon simultaneously. Three receptors. Three mechanisms. One protocol. Swipe to see what Retatrutide Results: 24% Weight Loss
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6














:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)









